AF
MNPR icon

Allworth Financial’s Monopar Therapeutics MNPR Stock Holding History

Allworth Financial’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3K Hold
111
– – ﹤0.01% 3692
2026
Q1 		$6.08K Buy
111
+11
+11% +$664 ﹤0.01% 3840
2025
Q4 		$6.53K Hold
100
– – ﹤0.01% 3551
2025
Q3 		$8.17K Hold
100
– – ﹤0.01% 3268
2025
Q2 		$3.58K Hold
100
– – ﹤0.01% 3448
2025
Q1 		$4.46K Buy
+100
New +$3.6K ﹤0.01% 2823

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Allworth Financial's MNPR Position: Q2 2026 in Review

Allworth Financial held its Monopar Therapeutics (MNPR) position steady in Q2 2026 at 111 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3692.

Allworth Financial first reported a position in MNPR in Q1 2025 and has held it in 6 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Allworth Financial held 111 shares of Monopar Therapeutics worth $10.3K as of Q2 2026.
  • Allworth Financial left its Monopar Therapeutics share count unchanged in Q2 2026.
  • Monopar Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3692 holding.
  • Allworth Financial first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.